The expanding success of T cell-engaging bispecific antibodies

T cell-based immunotherapies have revolutionized cancer treatment, and strategies to redirect T cells to recognize cancer cells are being investigated both preclinically and clinically. Bispecific T cell-engagers are antibodies that simultaneously bind to an antigen on tumor cells and a surface molecule on T cells. They have shown impressive activity in B cell malignancies and are being explored in many other cancer entities.